글로벌 쿠싱병 시장 – 2029년까지의 산업 동향 및 예측

시장 분석 및 규모

최근 몇 년 동안 쿠싱 증후군 시장은 예측 기간 동안 빠르게 성장할 것으로 예상됩니다. 쿠싱 증후군은 호르몬 코르티솔 수치가 높아서 나타나는 증상의 그룹입니다. 과코르티솔증이라고도 알려진 이 증후군은 코르티코스테로이드 약물의 부작용으로 인해 자주 발생합니다. 염증과 자가면역 질환은 일반적으로 코르티코스테로이드로 치료합니다. 의인성 쿠싱 증후군과 내인성 쿠싱 증후군은 쿠싱 증후군의 두 가지 종류입니다. 체중 증가, 복부와 등 주변의 지방 조직 축적, 보라색 튼살, 쉽게 멍이 드는 얇은 피부, 여드름 및 기타 증상이 일반적입니다.

Data Bridge Market Research는 쿠싱병 시장이 2021년에 3억 3,380만 달러 규모였으며 2029년까지 6억 8,689만 달러에 도달할 것으로 예상하고 2022년부터 2029년까지의 예측 기간 동안 9.44%의 CAGR을 기록할 것으로 분석했습니다. Data Bridge Market Research 팀이 큐레이팅한 시장 보고서에는 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크가 포함되어 있습니다.

시장 정의

고혈압, 붉은색 튼살, 복부 비만, 둥글고 붉은 얼굴, 약한 근육, 약한 뼈, 어깨 사이의 지방량, 느리게 치유되는 섬세한 피부는 모두 쿠싱 증후군의 증상이자 지표입니다. 쿠싱 증후군은 두 가지 주요 요인으로 인해 발생합니다. 프레드니손과 같은 과도한 코르티솔 유사 약물과 부신이 코르티솔을 과도하게 생산하여 형성된 종양입니다. 다발성 내분비선 신생물 1형 및 카니 복합체를 포함한 유전적 질환과 관련된 종양과 같은 다른 종양이 이 질환의 원인이 될 수 있습니다. 대부분의 경우 수술, 방사선 및 화학 요법을 결합하여 이 질환을 치료하고 완치할 수 있습니다.

보고 범위 및 시장 세분화

쿠싱병 시장 동향

운전자

• 쿠싱병 유병률 증가

쿠싱병의 유병률 증가는 시장 성장을 촉진할 것으로 추정됩니다. 쿠싱 증후군은 Orphanet Journal of Rare Disease에 따르면 연간 발병률은 100만 명당 1~3건으로 예상되지만, 2012년에는 100만 명당 40건에 가까웠습니다. 쿠싱 증후군은 과코르티솔증이라고도 하며, 신체 조직이 과도한 양의 호르몬 코르티솔에 지속적으로 노출되는 것을 특징으로 하는 호르몬 질환입니다. 쿠싱 증후군은 20~50세 성인에게 영향을 미칩니다.

• 의료 인프라에 대한 투자 증가

쿠싱병 시장의 성장률에 영향을 미치는 또 다른 중요한 요인은 인프라를 개선하는 데 도움이 되는 의료비 지출 증가입니다. 또한, 다양한 정부 기관은 자금을 늘려 의료 인프라를 개선하고자 하며, 이는 시장 역학에 더욱 영향을 미칠 것입니다.

• 노령 인구의 증가

The surging geriatric population is estimated to enhance the market's expansion during the forecast period of 2022-2029. According to the World Health Organization (WHO), the worldwide geriatric population, which was estimated to be over 524 million in 2010, is expected to increase to nearly 2 billion by 2050. Due to their compromised immune systems, geriatrics are more susceptible to get Cushing's disease, further estimated to enhance the market's growth rate. Cushing's disease is uncommon, however, it is at risk of developing in obese patients with type 2 diabetes, high blood pressure, and poorly regulated blood glucose.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the Cushing's disease market. Additionally, changing lifestyles of people and rising level of disposable income will result in the expansion of Cushing's disease market.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the Cushing's disease market growth. Along with this, rising drug approvals and launches will further propel the market's growth rate. 

Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will provide beneficial opportunities for Cushing's disease market growth during the forecast period.

Restraints/Challenges

On the other hand, high cost high cost associated with the treatment will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the Cushing's disease market. Additionally, strict regulatory policies and lack of awareness among people will restrain and further impede the growth rate of the market during the forecast period of 2022-2029.

This Cushing's disease market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Cushing's disease market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Cushing's disease market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Cushing's Disease Market

Since its emergence in December 2019, the COVID-19  virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. COVID-19, a new coronavirus, was identified as the causal agent in the pneumonia cases. This virus spread quickly over the world, killing a large number of people. COVID-19 was labelled a global pandemic by the World Health Organization (WHO) in March 2020, and rigorous measures to prevent the disease's spread were recommended. Since then, the pandemic has delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in many nations had imposed nationwide lockdowns to halt the spread of COVID-19. Similarly, healthcare organizations in numerous nations throughout the world were having difficulty continuing their supply chain activities. The Cushing's disease market was hampered by the supply chain slowness.

Recent Development

• In March 2020, the U.S. Food and Drug Administration (FDA) announced the approval of Isturisa (osilodrostat) oral tablets for adults suffering from Cushing's disease who cannot undergo pituitary gland surgery or have undergone the surgery but still have the disease. Isturisa is the first FDA-approved medicine to directly target cortisol overproduction by inhibiting the enzyme 11-beta-hydroxylase and stopping cortisol manufacture.

Global Cushing's Disease Market Scope

The Cushing's disease market is segmented on the basis of treatment type, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment Type

• Surgery
• Radiation Therapy
• Drugs
  • Ketoconazole
  • Mitotane
  • Aminoglutethimide
  • Metyrapone
  • Mifepristone
  • Etomidate
  • Pasireotide
  • Others

Diagnosis

• Petrosal Sinus Sampling
• Saliva Test
• Urine and Blood Tests
• Imaging Tests
  • Computerized tomography (CT) scans
  • Magnetic resonance imaging (MRI)
  • Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Cushing's Disease Market Regional Analysis/Insights

The Cushing's disease market is analysed and market size insights and trends are provided by country, treatment type, diagnosis, route of administration, end-users and distribution channel as referenced above.

The countries covered in the Cushing's disease market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the Cushing's disease market because of the rising number of research activities and the growing prevalence of obesity population in this region. Additionally, rising healthcare expenditure and favorable government policies will further propel the market's growth rate in this region.

Asia-Pacific are expected to grow during the forecast period due to the increasing level of disposable income in this region. Also, the development of healthcare infrastructure and rising awareness about the diseases will further propel the market's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Cushing's Disease Market Share Analysis

The Cushing's disease market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Cushing's disease market.

Some of the major players operating in the Cushing's disease market are:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (US)
• Teva Pharmaceutical Industries Ltd.(Israel)
• Sanofi (France)
• Pfizer Inc. (US)
• GlaxoSmithKline plc (UK)
• Novartis AG (Switzerland)
• Zydus Cadila (India)
• AstraZeneca (UK)
• Johnson & Johnson (US)
• Bayer AG(독일)
• Sun Pharmaceutical Industries Ltd. (인도)
• 브리스톨-마이어스 스퀴브 회사(미국)
• 엘리 릴리 앤드 컴퍼니(미국)
• Strides Pharma Science Limited(인도)
• 시플라 주식회사(미국)
• LEO Pharma A/S(덴마크)
• Aurobindo Pharma(인도)
• 루팡(인도)
• 히크마 제약(영국)

SKU-54306